Efficacy and safety of the combination therapy with Ipragliflozin for the cases who have insufficient effect by oral hypoglycemic agents - Effect of Ipragliflozin combination

ational Hospital Organization Kyoto Medical Center0 个研究点目标入组 32 人开始时间: 2015年2月17日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 32

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The patients' diminished estimated glomerular filtration rate (eGFR) was alleviated in the ipragliflozin group compared to the control group prior to significant improvements in HbA1c and other parameters, including anthropometric indices and arterial stiffness. Furthermore, ipragliflozin add-on therapy resulted in a greater reduction in serum UA levels than control therapy. The changes in the eGFR with ipragliflozin treatment were associated with ipragliflozin-mediated changes in the UA.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 80years-old（—）
性别: All

入选标准

未提供

排除标准

•1.Type 1 diabetes mellitus 2.Subjects with severe ketosis, diabetic coma or precoma 3.Subjects with severe infection, before and after surgery or severe injury 4.Subjects with severe hepatic dysfunction 5.Subjects with moderate renal dysfunction (Serum creatinine: more than 1.5mg/dL in male, more than 1.3mg/dL in female) 6.The subjects within the past 6 months, developed stroke, myocardial infarction, or other serious vascular complications requiring hospitalization 7.Sunjects with dehydration, diarrhea, vomiting or gastrointestinal injury 8.Subjects in SGLT-2 inhibitors, insulin formulation, GLP-1 receptor agonist prescription 9.Subjects in pregnant women, lactating women, the potential or planned are pregnant 10.Subjects with a history of hypersensitivity to SGLT-2 inhibitor 11.Subjects who have been determined to be unsuitable for the attending physician

研究者

发起方

ational Hospital Organization Kyoto Medical Center

相似试验

尚未招募

不适用

Treatment of Patients With Diabetic Kidney DiseaseDiabetic Kidney Disease

NCT06187493Assiut University70

终止

不适用

Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or ZnChronic Kidney Failure

NCT00399256Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)60

已完成

1 期

Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy PeopleHealthy Volunteers

NCT00543647Solvay Pharmaceuticals24

终止

4 期

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaType 2 Diabetes Mellitus

NCT03118713Astellas Pharma Korea, Inc.33

已完成

不适用

GFR Measurement With Contrast-enhanced Dynamic MRITransplantation, KidneyGraft Occlusion, Vascular

NCT00614081University Hospital, Bordeaux71